Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Technosphere® Insulin
Technosphere Powder
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria:
- HbA1c > or = to 7.5% and < or = to 10.0%
- Body mass index (BMI) < or = to 45 kg/m2
- Non smoker for at least 6 months before Screening
- Clinical diagnosis of type 2 diabetes mellitus for more than 12 months
Currently receiving as diabetes treatment only metformin or 2 or more OADs and on stable doses for at least 3 months before enrollment
- Subjects receiving metformin must be on at least 1.5gm daily, or up to the maximum tolerated dose
- Subjects treated with a sulfonylurea must be on at least 50% of the total maximum approved dose for a given agent
- Subjects receiving a DPP-4 inhibitor must receive the maximum approved dose specific for that agent
- Metiglinide and alpha-glucoside inhibitors must be taken at the highest tolerated dose within the approved dose range
- No previous or current treatment with insulin, except during an acute illness, gestational diabetes, or at time of initial diagnosis of diabetes
- Forced expiratory volume in one second (FEV1) > or = to 70% Third National Health and Nutrition Examination Survey (NHANES III) predicted
- Forced vital capacity (FVC) > or = to 70% NHANES III predicted
- Forced expiratory volume in one second as a percentage of forced vital capacity (FEV1/FVC) > or = to NHANES III lower limit of normal (LLN)
Exclusion Criteria:
- History of chronic obstructive pulmonary disease (COPD), clinically proven asthma, or any other clinically important pulmonary disease (eg, pulmonary fibrosis)
- Any clinically significant radiological findings on screening chest x-ray
- Use of medications for asthma, COPD, or any other chronic respiratory conditions
- Evidence of serious complications of diabetes (proliferative retinopathy, autonomic neuropathy with symptoms of gastroparesis or cardiac arrhythmia; sensory neuropathy that makes manipulation of the Gen2C inhaler difficult)
- Renal disease or renal dysfunction
- Significant cardiovascular dysfunction or history thereof within 12 months of screening; serious arrhythmia, treatment with medications to control/treat arrhythmias; myocardial infarction; cardiac surgery; history of valvular heart disease
- Previous or current use of amiodarone
- Treatment with glucagon-like peptide-1 (GLP-1) analogs, thiazolidinediones (TZD), or weight loss drugs (eg, sibutramine, orlistat) within 3 months of screening
- History of pulmonary embolism or deep venous thrombosis in the 12 months before Screening
- History of recent blood transfusion (within previous 3 months) or diagnosis of hemoglobinopathies that may affect HbA1c measurements
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
TI inhalation powder
Technosphere powder
Arm Description
Technosphere® Insulin powder administered via the Gen2 inhaler added to 2 or more stable OADs
Technosphere powder (with no insulin) administered via the Gen2 inhaler added to 2 or more stable OADs
Outcomes
Primary Outcome Measures
Change From Baseline to Week 24 in HbA1c
Efficacy as measured by change in glycated hemoglobin (HbA1c) at Week 24
Secondary Outcome Measures
Proportion of Responders Achieving HbA1c <= 7.0%
Efficacy as measured in proportion of subjects achieving HbA1c < or = to 7.0%
Proportion of Responders Achieving HbA1c <= 6.5%
Efficacy as measured in proportion of subjects achieving HbA1c < or = to 6.5% at Week 24
FPG Change From Baseline to Week 24
Efficacy as measured by mean change in fasting plasma glucose (FPG)
Proportion of Subjects Requiring Rescue Therapy
Time to Rescue
Time from Week 0 (baseline) to initiation of rescue therapy (up to a maximum of 24 weeks/end of treatment) for subjects not responding to treatment
FEV1 Change From Baseline to Week 24
Forced Expiratory Volume in 1 second - change from baseline to week 24
Incidence of Total Hypoglycemia
Hypoglycemia, defined as blood glucose <= 70 mg/dL or in absence of blood glucose, symptoms that are resolved by the administration of carbohydrates.
Incidence of Severe Hypoglycemia
Severe Hypoglycemia defined as: Requiring 3rd party assistance.
Total Hypoglycemia Event Rate
Number of Hypoglycemic Events/Total Subject Exposure Time (in months)
Severe Hypoglycemia Event Rate
Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)
Mean 7-point Glucose Baseline Values
Mean 7-point self-monitored glucose at baseline
Mean 7-point Glucose Week 24 Values
Mean 7-point self-monitored blood glucose at Week 24
Change in Body Weight From Baseline to Week 24
Change in body weight from Baseline to Week 24
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01451398
Brief Title
Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Official Title
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Prandial Technosphere® Insulin Inhalation Powder Versus Technosphere Inhalation Powder in Insulin Naïve Subjects With Type 2 Diabetes Mellitus Poorly Controlled With Oral Antidiabetic Agents Over a 24 Week Treatment Period
Study Type
Interventional
2. Study Status
Record Verification Date
October 2014
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
June 2013 (Actual)
Study Completion Date
July 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mannkind Corporation
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Insulin-naive subjects with Type 2 Diabetes Mellitus who are sub-optimally controlled on either maximum tolerated dose of metformin or maximum tolerated dose of metformin plus one or two other oral anti-diabetic medications will have either Prandial Technosphere® Insulin or Technosphere Powder (placebo) added to their oral antidiabetic drugs.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
353 (Actual)
8. Arms, Groups, and Interventions
Arm Title
TI inhalation powder
Arm Type
Experimental
Arm Description
Technosphere® Insulin powder administered via the Gen2 inhaler added to 2 or more stable OADs
Arm Title
Technosphere powder
Arm Type
Placebo Comparator
Arm Description
Technosphere powder (with no insulin) administered via the Gen2 inhaler added to 2 or more stable OADs
Intervention Type
Drug
Intervention Name(s)
Technosphere® Insulin
Intervention Description
Technosphere® Insulin Inhalation Powder
Intervention Type
Drug
Intervention Name(s)
Technosphere Powder
Intervention Description
Placebo Comparator
Primary Outcome Measure Information:
Title
Change From Baseline to Week 24 in HbA1c
Description
Efficacy as measured by change in glycated hemoglobin (HbA1c) at Week 24
Time Frame
Baseline to Week 24
Secondary Outcome Measure Information:
Title
Proportion of Responders Achieving HbA1c <= 7.0%
Description
Efficacy as measured in proportion of subjects achieving HbA1c < or = to 7.0%
Time Frame
Week 24
Title
Proportion of Responders Achieving HbA1c <= 6.5%
Description
Efficacy as measured in proportion of subjects achieving HbA1c < or = to 6.5% at Week 24
Time Frame
Week 24
Title
FPG Change From Baseline to Week 24
Description
Efficacy as measured by mean change in fasting plasma glucose (FPG)
Time Frame
Baseline to Week 24
Title
Proportion of Subjects Requiring Rescue Therapy
Time Frame
Baseline to Week 24
Title
Time to Rescue
Description
Time from Week 0 (baseline) to initiation of rescue therapy (up to a maximum of 24 weeks/end of treatment) for subjects not responding to treatment
Time Frame
Baseline to Week 24
Title
FEV1 Change From Baseline to Week 24
Description
Forced Expiratory Volume in 1 second - change from baseline to week 24
Time Frame
Baseline to Week 24
Title
Incidence of Total Hypoglycemia
Description
Hypoglycemia, defined as blood glucose <= 70 mg/dL or in absence of blood glucose, symptoms that are resolved by the administration of carbohydrates.
Time Frame
Baseline to Week 24
Title
Incidence of Severe Hypoglycemia
Description
Severe Hypoglycemia defined as: Requiring 3rd party assistance.
Time Frame
Baseline to Week 24
Title
Total Hypoglycemia Event Rate
Description
Number of Hypoglycemic Events/Total Subject Exposure Time (in months)
Time Frame
Baseline to Week 24
Title
Severe Hypoglycemia Event Rate
Description
Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)
Time Frame
Baseline to Week 24
Title
Mean 7-point Glucose Baseline Values
Description
Mean 7-point self-monitored glucose at baseline
Time Frame
Baseline
Title
Mean 7-point Glucose Week 24 Values
Description
Mean 7-point self-monitored blood glucose at Week 24
Time Frame
Week 24
Title
Change in Body Weight From Baseline to Week 24
Description
Change in body weight from Baseline to Week 24
Time Frame
Baseline to Week 24
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
HbA1c > or = to 7.5% and < or = to 10.0%
Body mass index (BMI) < or = to 45 kg/m2
Non smoker for at least 6 months before Screening
Clinical diagnosis of type 2 diabetes mellitus for more than 12 months
Currently receiving as diabetes treatment only metformin or 2 or more OADs and on stable doses for at least 3 months before enrollment
Subjects receiving metformin must be on at least 1.5gm daily, or up to the maximum tolerated dose
Subjects treated with a sulfonylurea must be on at least 50% of the total maximum approved dose for a given agent
Subjects receiving a DPP-4 inhibitor must receive the maximum approved dose specific for that agent
Metiglinide and alpha-glucoside inhibitors must be taken at the highest tolerated dose within the approved dose range
No previous or current treatment with insulin, except during an acute illness, gestational diabetes, or at time of initial diagnosis of diabetes
Forced expiratory volume in one second (FEV1) > or = to 70% Third National Health and Nutrition Examination Survey (NHANES III) predicted
Forced vital capacity (FVC) > or = to 70% NHANES III predicted
Forced expiratory volume in one second as a percentage of forced vital capacity (FEV1/FVC) > or = to NHANES III lower limit of normal (LLN)
Exclusion Criteria:
History of chronic obstructive pulmonary disease (COPD), clinically proven asthma, or any other clinically important pulmonary disease (eg, pulmonary fibrosis)
Any clinically significant radiological findings on screening chest x-ray
Use of medications for asthma, COPD, or any other chronic respiratory conditions
Evidence of serious complications of diabetes (proliferative retinopathy, autonomic neuropathy with symptoms of gastroparesis or cardiac arrhythmia; sensory neuropathy that makes manipulation of the Gen2C inhaler difficult)
Renal disease or renal dysfunction
Significant cardiovascular dysfunction or history thereof within 12 months of screening; serious arrhythmia, treatment with medications to control/treat arrhythmias; myocardial infarction; cardiac surgery; history of valvular heart disease
Previous or current use of amiodarone
Treatment with glucagon-like peptide-1 (GLP-1) analogs, thiazolidinediones (TZD), or weight loss drugs (eg, sibutramine, orlistat) within 3 months of screening
History of pulmonary embolism or deep venous thrombosis in the 12 months before Screening
History of recent blood transfusion (within previous 3 months) or diagnosis of hemoglobinopathies that may affect HbA1c measurements
Facility Information:
City
Anaheim
State/Province
California
ZIP/Postal Code
92807
Country
United States
City
Huntington Beach
State/Province
California
ZIP/Postal Code
92648
Country
United States
City
Laguna Hills
State/Province
California
ZIP/Postal Code
92653
Country
United States
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
City
Los Angeles
State/Province
California
ZIP/Postal Code
90036
Country
United States
City
Los Gatos
State/Province
California
ZIP/Postal Code
95032
Country
United States
City
Tustin
State/Province
California
ZIP/Postal Code
92780
Country
United States
City
West Hills
State/Province
California
ZIP/Postal Code
91307
Country
United States
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33012
Country
United States
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33021
Country
United States
City
Miami
State/Province
Florida
ZIP/Postal Code
33156
Country
United States
City
Miami
State/Province
Florida
ZIP/Postal Code
33173
Country
United States
City
New Port Richey
State/Province
Florida
ZIP/Postal Code
34652
Country
United States
City
North Miami Beach
State/Province
Florida
ZIP/Postal Code
33179
Country
United States
City
Pembroke Pines
State/Province
Florida
ZIP/Postal Code
33026
Country
United States
City
Pinellas Park
State/Province
Florida
ZIP/Postal Code
33781
Country
United States
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33401
Country
United States
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30308
Country
United States
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30318
Country
United States
City
Dunwoody
State/Province
Georgia
ZIP/Postal Code
30338
Country
United States
City
Lawrenceville
State/Province
Georgia
ZIP/Postal Code
30045
Country
United States
City
Roswell
State/Province
Georgia
ZIP/Postal Code
30076
Country
United States
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60607
Country
United States
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70808
Country
United States
City
Edina
State/Province
Minnesota
ZIP/Postal Code
55435
Country
United States
City
Jefferson City
State/Province
Missouri
ZIP/Postal Code
65109
Country
United States
City
St Peters
State/Province
Missouri
ZIP/Postal Code
63376
Country
United States
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63117
Country
United States
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68114
Country
United States
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68131
Country
United States
City
Clifton
State/Province
New Jersey
ZIP/Postal Code
07012
Country
United States
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
City
Paramus
State/Province
New Jersey
ZIP/Postal Code
07652
Country
United States
City
Flushing
State/Province
New York
ZIP/Postal Code
11365
Country
United States
City
New Hyde
State/Province
New York
ZIP/Postal Code
11042
Country
United States
City
Greenville
State/Province
North Carolina
ZIP/Postal Code
27834
Country
United States
City
Perrysburg
State/Province
Ohio
ZIP/Postal Code
43551
Country
United States
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
City
Greer
State/Province
South Carolina
ZIP/Postal Code
29651
Country
United States
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38119
Country
United States
City
Arlington
State/Province
Texas
ZIP/Postal Code
76014
Country
United States
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
City
Houston
State/Province
Texas
ZIP/Postal Code
77095
Country
United States
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78249
Country
United States
City
Magna
State/Province
Utah
ZIP/Postal Code
84044
Country
United States
City
Renton
State/Province
Washington
ZIP/Postal Code
98057
Country
United States
City
Wenatchee
State/Province
Washington
ZIP/Postal Code
98801
Country
United States
City
Porto Alegre
ZIP/Postal Code
90035
Country
Brazil
City
Sao Paulo
ZIP/Postal Code
01244
Country
Brazil
City
Kemerovo
ZIP/Postal Code
650066
Country
Russian Federation
City
Leningrad Region
Country
Russian Federation
City
Moscow
ZIP/Postal Code
105120
Country
Russian Federation
City
Moscow
ZIP/Postal Code
117036
Country
Russian Federation
City
Moscow
ZIP/Postal Code
119435
Country
Russian Federation
City
Moscow
ZIP/Postal Code
119991
Country
Russian Federation
City
Moscow
ZIP/Postal Code
121374
Country
Russian Federation
City
Moscow
ZIP/Postal Code
129128
Country
Russian Federation
City
Moscow
ZIP/Postal Code
143420
Country
Russian Federation
City
Petrozavodsk
ZIP/Postal Code
185019
Country
Russian Federation
City
Smolensk
ZIP/Postal Code
214018
Country
Russian Federation
City
St. Petersburg
ZIP/Postal Code
194044
Country
Russian Federation
City
St. Petersburg
ZIP/Postal Code
194354
Country
Russian Federation
City
St. Petersburg
ZIP/Postal Code
195257
Country
Russian Federation
City
St. Petersburg
ZIP/Postal Code
196601
Country
Russian Federation
City
St. Petersburg
ZIP/Postal Code
198013
Country
Russian Federation
City
Yaroslavl
ZIP/Postal Code
150003
Country
Russian Federation
City
Yaroslavl
ZIP/Postal Code
150023
Country
Russian Federation
City
Kharkiv
State/Province
UKR
ZIP/Postal Code
61070
Country
Ukraine
City
Kiev
State/Province
UKR
ZIP/Postal Code
04053
Country
Ukraine
City
Kyiv
State/Province
UKR
ZIP/Postal Code
02175
Country
Ukraine
City
Odesa
State/Province
UKR
ZIP/Postal Code
65039
Country
Ukraine
City
Vinnytsya
State/Province
UKR
ZIP/Postal Code
21010
Country
Ukraine
City
Kiev
ZIP/Postal Code
04114
Country
Ukraine
12. IPD Sharing Statement
Citations:
PubMed Identifier
26253730
Citation
Rosenstock J, Franco D, Korpachev V, Shumel B, Ma Y, Baughman R, Amin N, McGill JB; Affinity 2 Study Group. Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naive Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents. Diabetes Care. 2015 Dec;38(12):2274-81. doi: 10.2337/dc15-0629. Epub 2015 Aug 7.
Results Reference
derived
Learn more about this trial
Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs